Trial reportJournal of cardiac failure2020
Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction.
Trial report in Journal of cardiac failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.European heart journal · 2024Trial
- Obesity in Cardiorenal syndrome: Management Opportunities and Challenges.Current hypertension reports · 2025Review
- Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.Journal of the American College of Cardiology · 2025Review
- Distinct blood volume and left ventricular adaptation to severe obesity in middle-aged adults at risk for heart failure.European journal of heart failure · 2025Article
- Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.Current heart failure reports · 2025Review
- Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.Frontiers in cardiovascular medicine · 2025Review
- Mitochondrial Reactive Oxygen Species Dysregulation in Heart Failure with Preserved Ejection Fraction: A Fraction of the Whole.Antioxidants (Basel, Switzerland) · 2024Review
- Review
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.Clinical cardiology · 2024Article
- Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling.Journal of clinical medicine · 2023Review
- Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets.Cardiovascular research · 2023Review
- Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2023Article
- Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?Cardiac failure review · 2023Review
- The HScientific reports · 2022Article
- Pathophysiological and diagnostic importance of fatty acid-binding protein 1 in heart failure with preserved ejection fraction.Scientific reports · 2021Article
- Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging.Nature reviews. Cardiology · 2021Review
- Proposal for New Classification and Practical Use of Diuretics According to Their Effects on the Serum Chloride Concentration: Rationale Based on the "Chloride Theory".Cardiology and therapy · 2020Review
- Evaluation and management of heart failure with preserved ejection fraction.Nature reviews. Cardiology · 2020Review
- Regional adiposity and heart failure with preserved ejection fraction.European journal of heart failure · 2020Review
- Range of adiposity and cardiorenal syndrome.World journal of diabetes · 2020Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPatients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity display a number of pathophysiologic features that may render them more or less vulnerable to negative effects of decongestion on renal function, including greater right ventricular remodeling, plasma volume expansion and pericardial restraint. We aimed to contrast the renal response to decongestion in obese compared to nonobese patients with HFpEF METHODS AND
resultsNational Institutes of Health heart failure network studies that enrolled patients with acute decompensated HFpEF (EF ≥ 50%) were included (DOSE, CARRESS, ROSE, and ATHENA). Obese HFpEF was defined as a body mass index ≥ 30 kg/m
conclusionsDespite being nearly a decade younger, obese patients with HFpEF experience greater deterioration in renal function during decongestion than do nonobese patients with HFpEF. Further study to elucidate the complex relationships between volume distribution, cardiorenal hemodynamics and adiposity in HFpEF is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.